【Adv.Funct.Mater.】港中深唐本忠院士等|活性骤升210倍、抑瘤率达84%!新型AIE光敏剂靶向降解CAIX引发肿瘤细胞铁死亡
【Adv.Funct.Mater.】港中深唐本忠院士等|活性骤升210倍、抑瘤率达84%!新型AIE光敏剂靶向降解CAIX引发肿瘤细胞铁死亡
文章标题:AIE Photosensitizer-Mediated Photodegradation of Carbonic Anhydrase IX Triggers Ferroptosis
文章作者:Xuxian Su, Bin Liu, Qian Cao, Ya-Ping Wang, Fei Wang, Kun Peng, Sheng-Yi Yang, Zhuo-Yang Xin, Jianwei Sun, Wen-Jin Wang, Zheng Zhao, Ryan T. K. Kwok, Jacky W. Y. Lam, Ben Zhong Tang
文章概要
本文报道了一项克服光动力疗法耐药性的突破性研究。香港中文大学(深圳)唐本忠院士及合作团队设计并合成了一款具有苯磺酰胺尾翼的聚集诱导发光光敏剂(TBC)。该分子能特异性结合肿瘤细胞膜表面过度表达的碳酸酐酶IX(CAIX),并在光照下促使其原位光降解。这种光降解过程有效地缓解了肿瘤缺氧微环境,同时诱导了细胞内酸中毒,并大幅提升了活性氧水平与脂质过氧化。这一双重机制打破了缺氧导致CAIX上调并引发光动力疗法耐药的恶性循环,成功触发了强效的细胞铁死亡。在体内实验中,该策略实现了高精度的肿瘤光动力治疗与抗肿瘤免疫激活,抑瘤率高达84%,为解决缺氧肿瘤的治疗耐药问题提供了全新思路。
引言
光动力疗法由于其无创性、高空间可控性以及低耐药风险,在肿瘤临床治疗中展现出巨大潜力。然而,该疗法极度依赖氧气,而实体肿瘤内部普遍存在缺氧微环境,这严重限制了光动力疗法的实际疗效。更棘手的是,光动力治疗过程本身对氧气的剧烈消耗会进一步加重肿瘤缺氧,促使低氧诱导因子(HIF-1α)上调表达,进而诱导碳酸酐酶IX(CAIX)等代谢相关蛋白的过量表达。CAIX作为一种重要的跨膜蛋白,能够通过维持细胞内酸碱平衡和驱动糖酵解来帮助肿瘤细胞在缺氧环境下生存,这直接构成了肿瘤对光动力疗法产生耐药的主要屏障。此外,肿瘤缺氧还会抑制细胞的铁死亡过程,使得常规治疗手段难以奏效。为了打破缺氧、CAIX上调与光动力耐药之间的恶性循环,研究团队提出了利用显色团辅助光灭活技术,开发兼具CAIX靶向抑制与高效产氧能力的光敏剂,从而实现蛋白原位光降解与铁死亡诱导的协同抗肿瘤策略。

Scheme 1 Schematic illustration of the AIE PS TBC: in situ photodegradation of CAIX triggers ferroptosis by alleviating hypoxia and inducing intracellular acidosis.
主要实验及结论
在分子设计上,研究团队以苯磺酰胺作为活性靶向基团,成功构建了具有典型聚集诱导发光特性的光敏剂分子TBC,并设计了缺乏苯磺酰胺基团的对照分子TBN(如示意图1所示)。理化性质测试表明,TBC在纯水中的发射峰位于750纳米附近,且随着水相比例的增加表现出显著的聚集诱导发光效应,其发光强度在水相比例达到80%时提升了15倍(如图1所示)。理论计算表明,TBC分子具有明显的电荷转移(CT)特性,其单重态到三重态的自旋轨道耦合强度显著高于对照分子,这赋予了TBC极为出色的Ⅰ型和Ⅱ型活性氧生成能力。在光照条件下,TBC能够高效产生超氧阴离子、羟基自由基以及单线态氧,为其发挥高活性的光动力毒性奠定了物理化学基础。

Fig.1 (A) Normalized fluorescence (FL) spectra of TBN and TBC in THF and DMSO. (B) Plots of the relative FL intensity (I/_I_0)) of TBN and TBC as a function of the water fraction (_f_w) in DMSO/water mixtures. _I_0 = FL intensity in pure DMSO. _λ_ex = 450 nm. (C) Peak maximum of TBC as a function of the water fraction (_f_w) in DMSO/water mixtures. (D) Plot of the relative FL intensity (I/_I_0, _λ_ex = 488 nm) of DCF versus irradiation time in DMSO/water mixtures with varied _f_w in the presence of 10 µM TBC under white light irradiation (20 mW cm−2), where _I_0 is the pre-irradiation FL intensity of DCF. (E) Detection of total ROS via DCF. (F) Detection of O2**·**− via oxidation of DHR123 (_λ_ex = 495 nm, _λ_em = 525 nm). (G) Detection of **·**OH via HPF (_λ_ex = 490 nm, _λ_em = 515 nm). (H) Detection of 1O2 via bleaching of ABDA (_λ_abs = 525 nm). (I and J) Electron density distributions of the HOMO and LUMO for TBC and TBN based on DFT calculations.
细胞及分子水平的靶向性实验证实,TBC能够通过其苯磺酰胺尾翼精准结合CAIX蛋白(如图2所示)。分子对接与质谱分析显示,TBC能够深入CAIX的活性口袋并与锌离子发生配位,其结合能达到-7.1 kcal/mol,结合后分子的荧光寿命从3.6纳秒延长至5.2纳秒,证明分子运动受到了有效限制。酶活性抑制实验表明,TBC对CAIX的黑暗抑制半数抑制浓度为145.1 nM,而在光照10分钟后,其抑酶活性显著提升至0.68 nM,抑制效力猛增了210倍(如图3所示)。凝胶电泳与质谱结果表明,光照下的TBC通过产生活性氧诱导了CAIX蛋白发生选择性交叉联结与断裂降解。这种光降解效应不仅显著降低了MDA-MB-231细胞中CAIX和HIF-1α的表达量,还成功提升了细胞内的氧气浓度,缓解了细胞缺氧状态,并引发了显著的细胞内酸中毒。

Fig.2 (A) Colocalization of TBN (2 µm, 0.5 h) with BODIPY 493/503 or TBC (2 µm, 0.5 h) with Dil in MDA-MB-231 cells. TBN/TBC: _λ_ex = 450 nm, _λ_em = 660 ± 30 nm; BODIPY: _λ_ex = 493 nm, _λ_em = 520 ± 20 nm; Dil: _λ_ex = 561 nm, _λ_em = 590 ± 20 nm; Scale bar: 10 µm. Colocalization analysis was performed using the Coloc 2 plugin in ImageJ/Fiji. (B) Molecular docking of TBC with CAIX (PDB code: 3IAI). Zn2+ was shown as a gray sphere. (C) MALDI-TOF MS analysis of TBC upon incubation with CAIX. (D) Changes in the fluorescent lifetimes of TBN and TBC upon incubation with CAIX.

Fig.3 (A) SDS-PAGE analysis of CAIX incubated with TBC (left) or TBN (right) under the indicated conditions (dark/light, normoxic/hypoxic). Lane 1/8/15: Ladder; Lane 2/9: CAIX (dark); Lane 3/10: CAIX under normoxia (light); Lane 4/11: CAIX under hypoxia (light); Lane 5/12: CAIX + 1 eq. TBC/TBN (dark); Lane 6/13: CAIX + 1 eq. TBC/TBN under normoxia (light); Lane 7/14: CAIX + 1 eq. TBC/TBN under hypoxia (light). (B) Inhibitory effect of TBC on the activity of CAIX isoforms measured by in vitro kit test. Data are presented as mean ± SD (n = 3). (C) Western blot analysis of CAIX and HIF-1α expression in MDA-MB-231 cells treated with TBC at indicated concentrations, under dark or light conditions. GAPDH served as the loading control. All Western blot bands were quantified by grayscale analysis using ImageJ/Fiji software, and the control group was set to 1.00. (D) Representative CLSM of intracellular hypoxia in cells treated with TBC or TBN for 24 h under hypoxia, with or without light irradiation. (E) pHi measurements in normoxic and hypoxic MDA-MB-231 cells following the indicated treatments (dark/light, 20 mW cm−2, 10 min). Data are presented as mean ± SD (n = 3). (F) Schematic illustration of TBC-mediated CAIX photodegradation, which amplifies the therapeutic effect through hypoxia alleviation and cellular acidosis.
深入的细胞毒性机制研究表明,铁死亡抑制剂能够显著恢复TBC光照处理后的细胞活力,透射电镜观察也证实细胞出现了线粒体体积缩小、膜密度增加等典型的铁死亡形态学特征(如图4所示)。生化分析表明,TBC介导的光动力作用导致细胞内GPX4和xCT蛋白表达下调,还原型谷胱甘肽显著耗竭,丙二醛积累量大幅上升,证明细胞内积累了致命的脂质过氧化物。亚细胞定位追踪发现,TBC展现出独特的时空级联靶向特性,在孵育30分钟时优先定位于细胞膜,而在6至12小时内逐渐转移并富集于高尔基体与内质网(如图5所示)。光照引发的局部氧化应激导致了高尔基体碎裂以及内质网网状结构破坏,进而诱发了严重的内质网应激与钙离子释放,极大放大了脂质过氧化效应。转录组测序分析进一步证实,受TBC光动力处理影响的基因显著富集于内质网蛋白加工、谷胱甘肽代谢、钙信号通路及铁死亡等关键代谢路径(如图6所示)。

Fig.4 (A) Characterization of specific ROS produced in MDA-MB-231 cells upon TBC-mediated PDT. Total ROS levels after TBC + Light treatment were measured by CLSM in cells pre-incubated with the indicated ROS inhibitors. (B) Effects of various inhibitors on TBC-mediated photocytotoxicity. Cell viability was measured by MTT assay in MDA-MB-231 cells that were pre-incubated for 1 h with the indicated inhibitors and then treated with TBC + Light (2 µm, 20 mW cm−2, 10 min) (n = 3). (C) TEM images of TBC + Light-treated MDA-MB-231 cells under light irradiation. (D) Western blot analysis of GPX4, xCT, and GAPDH expression in MDA-MB-231 cells after treatment with TBC + Light. Impact of TBC on the ratios of GSSG/GSH (E) and MDA (F). All data are presented as mean ± SD (n = 3). Statistical significance was determined using one‑way analysis of variance (ANOVA). (G) Schematic illustration of TBC-mediated CAIX photodegradation inducing ferroptosis.

Fig.5 (A) CLSM images of MDA-MB-231 cells collected at different times after TBC or TBN treatment (2 µm). TBC/TBN: _λ_ex = 450 nm, _λ_em = 660 ± 30 nm. Scale bar: 10 µm. (B) Colocalization of TBC with Golgi (left) and ER (right)

Fig.6 RNA sequencing. (A–C) Gene ontology categorization of cellular component, molecular function and biological process for assembled unigenes of the transcriptome induced by TBC + Light treatment (2 µm, 20 mW cm−2, 10 min). (D) KEGG enrichment analysis of differentially expressed genes after TBC + Light treatment. (E) GSEA demonstrated significant enrichment of pathways involved in biological, metabolic, and immune functions in the TBC + Light-treated groups.probes in MDA‑MB‑231 cells (2 µm, 12 h). BODIPY TR ceramide/ER-Tracker Red: _λ_ex = 560 nm, _λ_em = 615 ± 20 nm. Scale bar: 5 µm. (C) TEM images of MDA-MB-231 cells after treatment with TBC + Light (2 µm, 20 mW cm−2, 10 min). (D) Western blot of GRASP55, GM130, p-IRE1, CHOP, and GAPDH expression in MDA-MB-231 cells after treatment with TBC + Light. (E) CLSM images of intracellular Ca2+ assays with Fluo-4 AM in MDA-MB-231 cells after treatment with TBC + Light. Scale bar: 20 µm. (F) Spatiotemporal cascade targeting of TBC: from cell membrane to Golgi/ER stress and ferroptosis.
TBC诱导的细胞铁死亡同时展现出强烈的免疫原性。免疫荧光与生化检测显示,光照处理后的肿瘤细胞表面钙网织蛋白表达量剧增,高核黄素蛋白HMGB1从细胞核向细胞质迁移,并且细胞外ATP分泌量呈剂量依赖性增加(如图7所示)。在同种移植4T1乳腺癌小鼠模型中,TBC结合光照治疗展现出卓越的体内抑瘤效果,小鼠肿瘤生长抑制率高达84%,且未观察到明显的全身毒副作用或主要器官损伤。流式细胞术分析表明,该治疗策略显著促进了肿瘤组织中树突状细胞的成熟,成熟度从9.7%提升至42.4%,同时使辅助性CD4+ T细胞和杀伤性CD8+ T细胞的浸润比例分别大幅提升至69.2%与22.2%,成功激活了强效的抗肿瘤适应性免疫应答。

Fig.7 In vivo anti-tumor efficacy and anti-tumor immune response. (A) CLSM analysis of ecto-CRT and HMGB1 in MDA-MB-231 cells after treatment with TBC + Light (2 µm, 20 mW cm−2, 10 min). Scale bar: 20 µm. (B) ATP levels in cell culture supernatants after treatment with TBC + Light. Data are presented as mean ± SD (n = 3). Statistical significance was determined using one‑way analysis of variance (ANOVA). (C) The photographs of the tumor were collected at the end of the therapeutic period. (D) Volume changes of the tumors: (grey dot) Ctrl, (black dot) Ctrl + Light, (light red dot) TBC, (red dot) TBC + Light. Data are presented as mean ± SD (n = 5). Populations of CD80/CD86 (E), CD4+ (F) and CD8+ T cells (G) in tumors. Data are presented as mean ± SD (n = 3). Statistical significance was determined using an unpaired, two‑tailed Student’s t‑test. *p < 0.05, **p < 0.01, *p < 0.001.
总结及展望
综上所述,该研究成功开发了一种具有CAIX靶向能力的新型聚集诱导发光光敏剂TBC。该分子通过精准结合CAIX蛋白并引发原位光降解,不仅从根本上打破了缺氧与CAIX上调导致的光动力耐药恶性循环,还通过缓解肿瘤缺氧和诱导细胞内酸中毒,协同驱动了高活性的细胞铁死亡与免疫原性死亡。TBC所具备的膜-高尔基体-内质网时空级联靶向特性,进一步提升了光动力治疗在复杂肿瘤微环境中的精准度与杀伤力。这一将靶向蛋白降解与铁死亡诱导相结合的创新策略,为克服实体肿瘤光动力治疗耐药提供了极具临床转化前景的解决方案,并为开发针对其他低氧相关靶点的智能诊疗体系开辟了全新路径。
文章分享
如果这篇文章对你有帮助,欢迎分享给更多人!












